CCN2 and systemic sclerosis: In vivo, the anti-CCN2 antibody abrogated skin fibrosis in a mouse model of systemic sclerosis, concomitant with reduced cellular expression of platelet-derived growth factor beta (PDFGR-β), αSMA, phosphorylated SMAD, and fibroblast specific growth factor 1 [31].